Anti-GD2-chimeric-antigen-receptor-T-cell-therapy-Sinobioway-Cell-Therapy/prostate-specific-membrane-antigen-CAR-T-cell-therapy-Shanghai-Bioray-Laboratory-Inc: Cytokine release syndrome.

A 9-year-old boy with inflammatory myofibroblastic tumor (IMT) received anti-GD2-chimeric-antigen-receptor-T-cell-therapy-Sinobioway-Cell-Therapy and prostate-specific-membrane-antigen-CAR-T-cell-therapy-Shanghai-Bioray-Laboratory-Inc. After the first infusion, he developed grade-II cytokine release syndrome (CRS), which improved with treatment. He later experienced grade-I CRS after subsequent infusions, but it resolved on its own. The boy's symptoms completely relieved after the first CAR-T-cell-therapy infusion, but the tumor recurred after 688 days. He received chemotherapy and another infusion of anti-GD2-chimeric-antigen-receptor-T-cell-therapy-Sinobioway-Cell-Therapy, which controlled his fever and reduced the new tumor. He is currently being monitored. [Extracted from the article]